Obinutuzumab Injection

DRUG3 trials

Sponsors

Weill Medical College of Cornell University, Qianfoshan Hospital, Medical University Innsbruck

Conditions

Idiopathic Membranous NephropathyLeukemia, Lymphocytic, Chronic, B-CellMinimal Change Disease (MCD)

Phase 2

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

Active, not recruitingNCT05650723

Weill Medical College of Cornell UniversityLeukemia, Lymphocytic, Chronic, B-Cell

Start: 2023-05-08End: 2027-12-01Updated: 2026-02-25

A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)

RecruitingNCT07710157

Medical University InnsbruckMinimal Change Disease (MCD)

Start: 2026-07-13End: 2029-06-30Target: 48Updated: 2026-08-17

Unknown Phase

Obinutuzumab in the Management of Idiopathic Membranous Nephropathy

Qianfoshan HospitalIdiopathic Membranous Nephropathy

Start: 2023-07-31End: 2023-12-31Target: 30Updated: 2023-05-10